Please enable JavaScript or talk to your local administrator to get JavaScript enabled.
Skip filters
Skip facets
Funder
  • 152

  • 57

  • 29

  • 17

  • 16

  • 14

  • 12

  • 11

  • 10

  • 9

Funder Group
Research Organization
FOR (ANZSRC) Category
RCDC Category
Researcher
City
State
Country
Country of Funder
Start Year
Active Year
Similar Projects for

Project

Identifying Immunological Basis for Bladder Cancer Sex Bias

Funder: Canadian Institutes of Health Research

Funding period
CAD 60 K
USD 46 K
Funding amount
Abstract
Bladder cancer incidence shows an enigmatic male bias, as it is the 4th most common cancer in men but only the 12th most common cancer in women in Canada. The bias cannot be fully accounted for by lifestyle factors such as smoking, suggesting that it is likely a consequence of more fundamental biological differences between two sexes. To this end, we analyzed human primary bladder cancers and discovered that immune pathways are more enriched in women than in men, which hinted that sex bias may be driven by sex-specific differences in immune function. To address this possibility, we utilized the preclinical murine bladder cancer models that recapitulate the male bias seen in human bladder cancer. Remarkably, we observed that hormonally mediated differences in T cell immunity are responsible for sexual dimorphism in tumor growth. Our Research Proposal seeks to determine exact mechanisms by which sex hormones regulate T cell immunity. Male-based studies predominate in immunology research despite clear evidence that sex discrepancy exists in the outcome from many infectious and autoimmune diseases, vaccines and malignancies. Erroneous assumption that such results can be generalized to both sexes not only damages the scientific rigor and reproducibility but is also a major barrier to the long-term goal of personalizing treatments for immune-related diseases. Specific study design in our Proposal, explicitly aiming to highlight the immune mechanisms underlying unique protection against bladder cancer in females, presents an innovative approach to identify novel therapeutic targets. Also, completion of proposed research will establish an important insight that anti-tumor immunity may be largely different between men and women, thereby emphasizing sex as a critical biological variable to consider in designing future pre-clinical/clinical immunotherapy studies.

 
419
Projects
USD 227.1 M
Aggregated funding amount
USD 678 K
Average funding amount
Project list item
Intravesical delivery of an Fc-enhanced CD40 agonist antibody for the treatment of bladder cancer

Bladder Cancer Advocacy Network to Jeffrey Ravetch, David Knorr

USD 300,000
2020 - 2022
Project list item
Recombinant CCL2 as a novel treatment strategy for bladder cancer

Bladder Cancer Advocacy Network to Neelam Mukherjee, Robert Scott Svatek

USD 50,000
2020 - 2021
Project list item
Defining NRF2 induced tumor invasion in bladder cancer

Bladder Cancer Advocacy Network to Yuki Kita, William Youngkwan Kim, Bernard Weissman

USD 50,000
2020 - 2021
Project list item
Targeting regulatory B cells (Bregs) to improve anti-bladder cancer immunity

Bladder Cancer Advocacy Network to Burles Avner Johnson, David McConkey

USD 50,000
2020 - 2021
Project list item
Dissecting myeloid cell-mediated resistance to immune checkpoint blockade in bladder cancer

National Cancer Institute to NINA BHARDWAJ, JUN ZHU, MATTHEW GALSKY

USD 703,400
2020 - 2025
Project list item
Implication of neutrophil extracellular traps in the efficacy of bladder-sparing therapy in muscle invasive bladder cancer

Canadian Institutes of Health Research to Wassim Kassouf, Ciriaco A. Piccirillo, Jonathan David Spicer

USD 138,878
2020 - 2025
Project list item
Chimeric RNAs and their implication in lymphatic metastasis of bladder cancer

National Cancer Institute to HUI LI

USD 205,913
2020 - 2025
Project list item
CD40 agonism for the treatment of bladder cancer

National Cancer Institute to CHRISTOPHER STUART GARRIS

USD 64,554
2020 - 2023
Project list item
Effect of APOBEC3 on Bladder Cancer Biology and Response to Immunotherapy

National Cancer Institute to ANDREW TRUONG

USD 45,016
2020 - 2023
Project list item
A new bladder cancer model based on tissue reprogramming and gene targeting

National Cancer Institute to FLAMINIA TALOS, DAIFENG WANG

USD 203,843
2020 - 2021
Project list item
Roles of epigenetic regulators in bladder cancer progression

University of California - Cancer Research Coordinating Committee to Zhu Wang

USD 74,960
2020 - 2020
Project list item
Chemotherapy plus PD-1 blockade as bladder-sparing treatment for muscle-invasive bladder cancer

V Foundation for Cancer Research to Matthew D Galsky

USD 600,000
2019 - 2022
Project list item
Unravelling Mechanisms of Resistance to Checkpoint Inhibition in Canine Urothelial Carcinoma

V Foundation for Cancer Research to Nicola J. Mason

USD 500,000
2019 - 2021
Project list item
Engineering Smart Solutions for Disorders of the Bladder Urothelium

Engineering and Physical Sciences Research Council

 
2019 - 2023
Project list item
[The association between SORL1 and advanced bladder cancer] - Original in Japanese

Japan Society for the Promotion of Science to Takanobu UTSUMI

USD 26,335
2019 - 2021
Project list item
Developing a SMART scaffold for bladder augmentation

National Institute of Biomedical Imaging and Bioengineering to GUILLERMO ANTONIO AMEER, JOHN ROGERS, ARUN SHARMA

USD 1,399,891
2019 - 2023
load more...